Search Results

You are looking at 1 - 1 of 1 items for

  • Author or Editor: M. Camila Pardo x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To compare protection against FeLV challenge obtained following administration of 2 doses of an adjuvanted, chemically inactivated, whole FeLV (FeLV-k) vaccine with protection obtained following administration of 1 dose of an FeLV-k vaccine followed by 1 dose of a canarypox virus–vectored recombinant FeLV (rCP-FeLV) vaccine.

Design—Prospective study.

Animals—Thirty-two 9-week-old domestic shorthair cats.

Procedure—Cats received 2 doses of the FeLV-k vaccine SC, 21 days apart (n = 11); 1 dose of the FeLV-k vaccine SC and, 21 days later, 1 dose of the rCP-FeLV vaccine transdermally (11); or 2 doses of physiologic saline (0.9% NaCl) solution (control; 10). Four weeks after the second vaccine dose, all cats were challenged with FeLV by means of oronasal administration. Blood samples were collected at weekly intervals beginning 21 days after challenge, and serum was tested for FeLV antigen.

Results—All 10 control cats became persistently infected (ie, FeLV antigen detected in ≥ 3 consecutive serum samples) following FeLV challenge, whereas only 1 of 11 cats that received 2 doses of the FeLV-k vaccine and none of the 11 cats that received 1 dose of the FeLV-k vaccine and 1 dose of the rCP-FeLV vaccine did.

Conclusions and Clinical Relevance—Results suggest that protection against FeLV challenge obtained following SC administration of a single dose of an FeLV-k vaccine followed, 21 days later, by transdermal administration of a single dose of an rCP-FeLV vaccine was similar to that obtained following SC administration of 2 doses of the FeLV-k vaccine 21 days apart.

Restricted access
in Journal of the American Veterinary Medical Association